Long‐term‐effects of two principally different antidepressant drugs on saliva secretion and composition

Abstract

– In a double‐blind, controlled, cross‐over trial on 10 healthy volunteers, the effects of daily doses of maprotiline (75 mg) and zimelidine (100 mg) over a 14‐day period were tested on saliva secretion rate and saliva composition. Based on current knowledge of salivary gland physiology and the difference in specificity between the two drugs, differences in salivary gland response could be expected. Since both drugs have anticholinergic effects which influence saliva secretion rate, the measured component concentrations had to be recalculated with regard to dependencies of secretion rate. Maprotiline, but not zimelidine, caused strong inhibition of secretion rate and accommodation ability. Maprotiline consistently caused around 50% increases in concentrations of the following saliva components: protein, amylase, fucose, hexose, sialic acid and potassium. The effects of zimelidine were less pronounced and resulted in initial increases of most organic components. 14 and 18 h after the intake of the drug these increases had disappeared and some of the components instead showed decreased concentrations. The results are consistent with current theories about facilitated serotoninergic and noradrenergic transmissions during treatment with antidepressants.

The Effect of Chronic Atropine Treatment on Salivary Composition and Caries in Rats

“…Many instances of salivary dysfunction are related to the use of drugs with potential hyposalivary effects (Bertram et alt, 1979;Mornstad et at, 1986). Handelman et at (1986) described an institutionalized population in which at least half of the patients received one or more drugs with hyposalivary effects.…”

Efficacy and safety of a new oral saliva equivalent in the management of xerostomia: a national, multicenter, randomized study

“…[1][2][3][4][5][6][7][8][9] Xerostomia and its related complications may restrict daily activities and social life. [10][11][12][13][14][15][16] The management of xerostomia requires saliva stimulants (pilocarpine or cevimeline, two potent muscarinic receptor agonists enhancing saliva secretion or sialogogues, chewing, gustatory substances) often used in the treatment of Sjögren syndrome; and artificial saliva, including intraoral lubricating devices (or lactoperoxydase-enzyme-system containing toothpaste), saliva substitutes, or both.…”

Evaluation of Sialometric Analysis of Patients Suffering from Depressive Disorders

“…9 Studies done by Palmai G et al & Mörnstad H et al stated that the most pronounced reduction in the salivary flow rate was at rest. 10,11 TCA caused a more pronounced reduction than SSRIs. Imipramine (TCAs) reduced salivation by 12% and zimelidine (SSRIs) by 45.2%.…”